Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced the completion of phase 1 clinical studies for its LUCID-MS therapy, a patented candidate designed to target demyelination and provide neuroprotection in multiple sclerosis (MS). The therapy demonstrated a favorable safety profile and was generally well tolerated among healthy volunteers, marking a critical step toward addressing the underlying neurodegeneration and myelin damage that drive long-term disease progression.
Multiple sclerosis affects more than 2.8 million people worldwide, including approximately 1 million in the United States. Current treatments often focus on reducing inflammation and relapse frequency but may not adequately protect or restore myelin integrity, leaving many patients with worsening disability. Quantum BioPharma’s LUCID-MS program is built around this unmet need. In April 2026, the company reached a significant milestone by submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS.
“MS remains one of the most challenging neurological diseases due to its progressive nature and lack of a cure,” the company stated in its press release. By advancing a therapy that directly targets myelin repair, Quantum BioPharma aims to address the loss of mobility and bodily control that patients experience. The phase 1 results provide a foundation for further clinical development, with the IND submission setting the stage for potential phase 2 trials.
For ongoing updates, investors can visit the company’s newsroom at https://ibn.fm/QNTM. The therapy’s progress is being closely watched by the MS community, as disease-modifying treatments that can halt or reverse myelin damage remain a high priority. With millions affected globally, any advancement toward neuroprotection could significantly impact quality of life and disease management.
Quantum BioPharma’s focus on LUCID-MS highlights a broader shift in MS research toward regenerative approaches. While traditional immunomodulators reduce attacks, they often fail to prevent long-term disability. The LUCID-MS candidate, by targeting the core pathology of demyelination, represents a potential paradigm shift. The company’s successful phase 1 results and IND submission suggest that this approach is progressing toward clinical validation, offering hope for patients who currently have limited options for myelin repair.
As Quantum BioPharma moves forward, the next steps will involve further studies to confirm efficacy and safety in MS patients. The company’s commitment to addressing the root cause of MS disability underscores the importance of this work for the 2.8 million people worldwide living with the disease.
